Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CURIS INCCRIS · Entity 8401 | Director | February 28, 2017 | March 02, 2017 |
| Cue Biopharma, Inc.CUE · Entity 6301 | Chief Medical Officer | March 25, 2022 | March 29, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CURIS INC
Report date February 28, 2017 · Filed March 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock optionSEC Table II · derivative / convertible security · Conversion / exercise price $2.31 · Expires 2027-02-27 | Direct | 120,000 |
Reported balance
After 2017-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Options granted under the 2010 Amended and Restated Stock Incentive Plan and 1/12th of the total shares will vest monthly beginning on January 1, 2017 until all of the shares underlying the award become vested on January 1, 2018, subject to the director's continued service with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the 2010 Amended and Restated Stock Incentive Plan and 1/12th of the total shares will vest monthly beginning on January 1, 2017 until all of the shares underlying the award become vested on January 1, 2018, subject to the director's continued service with the Company.
Cue Biopharma, Inc.
Report date March 25, 2022 · Filed March 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.01 · Expires 2032-03-24 | Direct | 40,000 |
Reported balance
After 2022-03-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-25 · Grant · Acquired 40,000 · Balance 40,000 F1: 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 25, 2022 Filed Mar 29, 2022 16:12 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.01 | $0.00 |
DisclosureSEC source: 0001209191-22-021454 · doc4.xml · derivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: 1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022. Read SEC document |
| December 20, 2021 Filed Dec 21, 2021 16:05 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $11.45 | $0.00 |
DisclosureSEC source: 0000899243-21-049172 · doc4.xml · derivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-12-20 F1 · derivative.exercise_date: This stock option grant becomes exercisable in four equal semi-annual installments beginning June 20, 2022. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 439 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · derivative · entry 6 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,567 Underlying: Common Stock · 439 shares Expires 2024-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 439 | $15.09 | $6,625.65 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · nonDerivative · entry 4 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.22, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| March 16, 2021 Filed Mar 17, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 439 | $5.00 | $2,195.00 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · nonDerivative · entry 3 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,439 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 13,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · derivative · entry 5 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,006 Underlying: Common Stock · 13,000 shares Expires 2024-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 13,000 | $15.10 | $196,268.80 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · nonDerivative · entry 2 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.72, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| March 15, 2021 Filed Mar 17, 2021 16:00 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 13,000 | $5.00 | $65,000.00 |
DisclosureSEC source: 0001209191-21-021293 · doc4.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 2,994 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · derivative · entry 8 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,006 Underlying: Common Stock · 2,994 shares Expires 2024-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 1,280 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · derivative · entry 7 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,280 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 4,274 | $15.06 | $64,345.07 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 5 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 2,994 | $5.00 | $14,970.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 4 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 20:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 1,280 | $2.86 | $3,660.80 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 3 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 16,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · derivative · entry 6 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 Underlying: Common Stock · 16,000 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 16,000 | $15.15 | $242,422.40 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 2 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 to $15.60, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 20:44 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 16,000 | $2.86 | $45,760.00 |
DisclosureSEC source: 0000899243-21-007232 · doc4.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 17:52 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $15.55 | $0.00 |
DisclosureSEC source: 0000899243-21-006362 · doc4.xml · derivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-02-09 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 16:33 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 2,720 | $15.07 | $40,979.52 |
DisclosureSEC source: 0000899243-21-002947 · doc4.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,720 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.02 to $15.26, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| January 20, 2021 Filed Feb 18, 2021 20:40 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionStock Option (right to buy) · Derivative | 2,720 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0000899243-21-007230 · doc4a.xml · derivative · entry 3 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,280 Underlying: Common Stock · 2,720 shares Expires 2023-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F2 · shares: This option exercise was omitted from the reporting person's original Form 4. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017. Read SEC document |
| January 20, 2021 Filed Feb 18, 2021 20:40 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | SaleCommon Stock | 2,720 | $15.07 | $40,979.52 |
DisclosureSEC source: 0000899243-21-007230 · doc4a.xml · nonDerivative · entry 2 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F3 · kind: This transaction was incorrectly reported using Code "P" in the reporting person's original Form 4. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.02 to $15.26, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| January 20, 2021 Filed Feb 18, 2021 20:40 UTC Amendment | Cue Biopharma, Inc. CUE · Entity 6301 | Exercise / conversionCommon Stock | 2,720 | $2.86 | $7,779.20 |
DisclosureSEC source: 0000899243-21-007230 · doc4a.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,720 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020. F2 · shares: This option exercise was omitted from the reporting person's original Form 4. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 16:11 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001209191-20-021239 · doc4.xml · derivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-03-24 F1 · derivative.exercise_date: This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 24, 2020. Read SEC document |
| December 27, 2017 Filed Jan 19, 2018 17:03 UTC | Cue Biopharma, Inc. CUE · Entity 6301 | PurchaseCommon Stock | 2,000 | $7.50 | $15,000.00 |
DisclosureSEC source: 0001209191-18-004591 · doc4.xml · nonDerivative · entry 1 Pienta Kenneth · CIK 0001571862 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · shares: Reflects shares of the Issuer's common stock that were purchased in connection with the Issuer's initial public offering. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:56 UTC | CURIS INC CRIS · Entity 8401 | GrantNon-qualified stock option · Derivative | 120,000 | $0.00 Strike: $2.31 | $0.00 |
DisclosureSEC source: 0001209191-17-016742 · doc4.xml · derivative · entry 1 Pienta Kenneth · CIK 0001571862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: Options granted under the 2010 Amended and Restated Stock Incentive Plan and 1/12th of the total shares will vest monthly beginning on January 1, 2017 until all of the shares underlying the award become vested on January 1, 2018, subject to the director's continued service with the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.